Drug Trial Radar · NCT06249048
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
May 3, 2024
Primary completion
Jun 17, 2026
Study completion Jun 17, 2026
Sponsor
- Lead sponsor
- Strand Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.
Conditions
- Advanced Solid Tumor
Interventions
STX-001Biological
STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection. Injections may be administered into multiple lesions according to protocol-defined procedures.
Keytruda®Biological
Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and nature of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients with advanced solid tumors.Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).
- Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-001.Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
HonorHealth Research and Innovation Institute
Scottsdale, Arizona
NextGen Oncology
Beverly Hills, California
Cleveland Clinic
Cleveland, Ohio
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah
Melanoma Institute Australia
Wollstonecraft, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.